CY1124322T1 - Μεθοδος για τη βελτιωση της υδατικης διαλυτοτητας των αδιαλυτων στο νερο ή των ελαφρως-υδατοδιαλυτων φαρμακων - Google Patents
Μεθοδος για τη βελτιωση της υδατικης διαλυτοτητας των αδιαλυτων στο νερο ή των ελαφρως-υδατοδιαλυτων φαρμακωνInfo
- Publication number
- CY1124322T1 CY1124322T1 CY20211100218T CY211100218T CY1124322T1 CY 1124322 T1 CY1124322 T1 CY 1124322T1 CY 20211100218 T CY20211100218 T CY 20211100218T CY 211100218 T CY211100218 T CY 211100218T CY 1124322 T1 CY1124322 T1 CY 1124322T1
- Authority
- CY
- Cyprus
- Prior art keywords
- water
- insoluble
- dissolved
- organic compound
- slightly
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003125 aqueous solvent Substances 0.000 abstract 5
- 150000002894 organic compounds Chemical class 0.000 abstract 5
- 230000002209 hydrophobic effect Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 239000004378 Glycyrrhizin Substances 0.000 abstract 1
- 241000219287 Saponaria Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 abstract 1
- 229960004949 glycyrrhizic acid Drugs 0.000 abstract 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 abstract 1
- 235000019410 glycyrrhizin Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0291—Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201514801578A | 2015-07-16 | 2015-07-16 | |
| PCT/EP2016/066999 WO2017009480A1 (en) | 2015-07-16 | 2016-07-15 | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124322T1 true CY1124322T1 (el) | 2022-07-22 |
Family
ID=56418519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100218T CY1124322T1 (el) | 2015-07-16 | 2021-03-12 | Μεθοδος για τη βελτιωση της υδατικης διαλυτοτητας των αδιαλυτων στο νερο ή των ελαφρως-υδατοδιαλυτων φαρμακων |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP3324933B1 (https=) |
| JP (1) | JP6836825B2 (https=) |
| KR (1) | KR102615005B1 (https=) |
| CN (1) | CN107847440B (https=) |
| AU (1) | AU2016293125B2 (https=) |
| CA (1) | CA2992376C (https=) |
| CL (1) | CL2018000032A1 (https=) |
| CO (1) | CO2018001460A2 (https=) |
| CY (1) | CY1124322T1 (https=) |
| DK (1) | DK3324933T3 (https=) |
| EA (1) | EA036233B1 (https=) |
| ES (1) | ES2844581T3 (https=) |
| HR (1) | HRP20210333T1 (https=) |
| HU (1) | HUE053116T2 (https=) |
| IL (1) | IL256882B (https=) |
| LT (1) | LT3324933T (https=) |
| MA (1) | MA42472B1 (https=) |
| MX (1) | MX379341B (https=) |
| MY (1) | MY196065A (https=) |
| NZ (1) | NZ738592A (https=) |
| PH (1) | PH12018500042A1 (https=) |
| PL (1) | PL3324933T3 (https=) |
| PT (1) | PT3324933T (https=) |
| RS (1) | RS61561B1 (https=) |
| SA (1) | SA518390688B1 (https=) |
| SI (1) | SI3324933T1 (https=) |
| UA (1) | UA123312C2 (https=) |
| WO (1) | WO2017009480A1 (https=) |
| ZA (1) | ZA201708594B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108143713A (zh) * | 2018-01-04 | 2018-06-12 | 南方医科大学南方医院 | 一种增加羟喜树碱溶解度的方法 |
| US12377046B1 (en) | 2019-04-24 | 2025-08-05 | Wellomics LLC | Delivery system matrices |
| CN110074385B (zh) * | 2019-05-21 | 2022-05-31 | 绥化市蓝源生物工程有限公司 | 一种生物碱溶解纳他霉素的生物溶剂及其应用 |
| KR20220022829A (ko) * | 2020-08-19 | 2022-02-28 | 주식회사 모든바이오 | 글리시리진 및 수용성 약물을 포함하는 나노 입자, 이를 포함하는 약제학적 조성물 및 이들의 제조 방법 |
| CN114588118B (zh) * | 2022-01-25 | 2023-05-23 | 武汉爱民制药股份有限公司 | 一种注射用七叶皂苷钠复方制剂 |
| KR102922176B1 (ko) * | 2022-07-08 | 2026-02-04 | 한국생산기술연구원 | 소수성 약물 전달을 위한 금-히알루론산 나노입자의 제조방법 |
| EP4431082A1 (en) * | 2023-03-13 | 2024-09-18 | Marinomed Biotech AG | Aqueous composition comprising budesonide |
| EP4516289A1 (en) | 2023-08-30 | 2025-03-05 | SPH Sine Pharmaceutical Laboratories Co., Ltd | Antiviral nasal spray comprising favipiravir |
| CN117562911B (zh) * | 2023-12-07 | 2024-06-04 | 海南医学院 | 化合物tigloside在制备治疗和/或预防骨关节炎药物中的用途 |
| WO2025133675A1 (en) * | 2023-12-20 | 2025-06-26 | Melikoglu, Ahmet | Method for producing nasal formulation comprising aescin and rutin |
| EP4696300A1 (en) | 2024-08-14 | 2026-02-18 | Marinomed Biotech AG | Aqueous composition comprising fluticasone |
| KR102907892B1 (ko) * | 2025-01-09 | 2026-01-12 | 주식회사 한바이오 | 가용성을 높인 피레스로이드계의 보건용 스프레이 살충제 제조방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1119957A (en) | 1979-12-04 | 1982-03-16 | Martin Whitefield | Steroid compositions |
| US4782047A (en) | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
| US4868170A (en) | 1987-11-13 | 1989-09-19 | E. R. Squibb & Sons, Inc. | Steriod lotion formulation |
| JPH1025255A (ja) * | 1996-07-11 | 1998-01-27 | Taisho Pharmaceut Co Ltd | 溶解性の改善された難溶性薬剤 |
| FR2799369B1 (fr) | 1999-10-08 | 2001-12-21 | Oreal | Association d'escine et de sulfate de dextran et son utilisation |
| US7125564B2 (en) | 2001-02-16 | 2006-10-24 | Lavipharm Laboratories, Inc. | Water soluble and palatable complexes |
| JP4000283B2 (ja) * | 2002-08-07 | 2007-10-31 | 丸善製薬株式会社 | 甘草油性抽出物の可溶化組成物、並びに飲料、液状調味料、化粧品及び医薬部外品 |
| US7897587B2 (en) | 2004-09-03 | 2011-03-01 | Nycomed Us Inc. | Topical dermatological formulations and use thereof |
| JP5128801B2 (ja) * | 2006-10-16 | 2013-01-23 | フロイント産業株式会社 | 高水分散性粉末とその製造方法 |
| JP6265624B2 (ja) * | 2012-05-11 | 2018-01-24 | ロート製薬株式会社 | ルリコナゾール含有外用医薬組成物 |
| US9907846B2 (en) * | 2013-04-01 | 2018-03-06 | Mx Adjuvac Ab | Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions |
| CN103271891B (zh) * | 2013-04-28 | 2016-01-06 | 福建南方制药股份有限公司 | 人参皂苷纳米胶束及其制备方法、应用和药物组合物 |
| CN103520081B (zh) * | 2013-09-27 | 2015-10-28 | 无限极（中国）有限公司 | 一种调节皮肤免疫力、延缓皮肤老化的外用护肤品 |
-
2016
- 2016-07-15 SI SI201631114T patent/SI3324933T1/sl unknown
- 2016-07-15 MX MX2018000286A patent/MX379341B/es unknown
- 2016-07-15 EA EA201890194A patent/EA036233B1/ru unknown
- 2016-07-15 DK DK16739477.4T patent/DK3324933T3/da active
- 2016-07-15 MY MYPI2017704929A patent/MY196065A/en unknown
- 2016-07-15 HR HRP20210333TT patent/HRP20210333T1/hr unknown
- 2016-07-15 PT PT167394774T patent/PT3324933T/pt unknown
- 2016-07-15 KR KR1020187004268A patent/KR102615005B1/ko active Active
- 2016-07-15 NZ NZ738592A patent/NZ738592A/en unknown
- 2016-07-15 PL PL16739477T patent/PL3324933T3/pl unknown
- 2016-07-15 CN CN201680039722.5A patent/CN107847440B/zh active Active
- 2016-07-15 ES ES16739477T patent/ES2844581T3/es active Active
- 2016-07-15 HU HUE16739477A patent/HUE053116T2/hu unknown
- 2016-07-15 WO PCT/EP2016/066999 patent/WO2017009480A1/en not_active Ceased
- 2016-07-15 AU AU2016293125A patent/AU2016293125B2/en active Active
- 2016-07-15 EP EP16739477.4A patent/EP3324933B1/en active Active
- 2016-07-15 CA CA2992376A patent/CA2992376C/en active Active
- 2016-07-15 UA UAA201712614A patent/UA123312C2/uk unknown
- 2016-07-15 LT LTEP16739477.4T patent/LT3324933T/lt unknown
- 2016-07-15 JP JP2017566080A patent/JP6836825B2/ja active Active
- 2016-07-15 RS RS20210293A patent/RS61561B1/sr unknown
- 2016-07-15 MA MA42472A patent/MA42472B1/fr unknown
-
2017
- 2017-12-18 ZA ZA2017/08594A patent/ZA201708594B/en unknown
-
2018
- 2018-01-03 SA SA518390688A patent/SA518390688B1/ar unknown
- 2018-01-04 PH PH12018500042A patent/PH12018500042A1/en unknown
- 2018-01-05 CL CL2018000032A patent/CL2018000032A1/es unknown
- 2018-01-11 IL IL256882A patent/IL256882B/en unknown
- 2018-02-14 CO CONC2018/0001460A patent/CO2018001460A2/es unknown
-
2021
- 2021-03-12 CY CY20211100218T patent/CY1124322T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124322T1 (el) | Μεθοδος για τη βελτιωση της υδατικης διαλυτοτητας των αδιαλυτων στο νερο ή των ελαφρως-υδατοδιαλυτων φαρμακων | |
| CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
| CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
| BR112017023161A2 (pt) | composições de ácido obeticólico e métodos de uso | |
| BR112016028961A8 (pt) | fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| IN2014MN02213A (https=) | ||
| BR112016023872A2 (pt) | composição de resina adequada para impressão e método de impressão com o uso da mesma | |
| BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
| BR112018072248A2 (pt) | composições e métodos relacionados a imunógenos contra hiv-1 | |
| MX390860B (es) | Composiciones adyuvantes y metodos relacionados. | |
| MX2015009701A (es) | Proceso de obtencion de nonoparticulas biopolimericas conteniendo aceite y extractos de azadirachta indica a, juss (neem), nanoparticulas biopolimericas y microparticulas en polvo. | |
| CY1124529T1 (el) | Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου | |
| CY1124316T1 (el) | Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα | |
| CL2018000363A1 (es) | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana. | |
| CO2019013342A2 (es) | Formulaciones de medicamentos de moleculas pequeñas resistentes a la precipitación | |
| FR3058059B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
| BR112018007475A2 (pt) | ?solvente de extração e/ou solubilização, método para extrair compostos biológicos naturais, usos do solvente de extração e/ou solubilização e do extrato, e, extrato biológico natural? | |
| EA201691825A1 (ru) | Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта) | |
| EA202190328A1 (ru) | Фармацевтическая композиция, содержащая тикагрелор | |
| UY40072A (es) | Sal novedosa de un derivado de 1-sulfonilpirrol, método de preparación de la misma y composición far | |
| CY1125339T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν σαφιναμιδη | |
| BR112016028412A2 (pt) | composição farmacêutica, método para a preparação de uma composição farmacêutica, e kit | |
| FR3058060B1 (fr) | Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine. | |
| EP3524239A4 (en) | COMPOSITION WITH OLEANOLIC ACID ACETATE AS AN ACTIVE SUBSTANCE FOR PREVENTING, REDUCING OR TREATING MEDICINE-INDUCED KIDNEY TOXICITY |